NCT06301256

Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa

An Open-label Single Center Study to Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe Hidradenitis Suppurativa

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Florida Academic Centers Research and Education, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the clinical efficacy and safety of tirzepatide in subjects with moderate to severe hidradenitis suppurativa. The study will be conducted over 24 weeks on active therapy followed by a eight-week observational follow-up visit. The total length of the study will be 32 weeks .

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	TIRZEPATIDE	Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.

Timeline

• Start date: 2024-03-11
• Primary completion: 2025-03-11
• Completion: 2025-03-11
• First posted: 2024-03-08
• Last updated: 2024-03-08